[1]卫延辉,郭学军.嵌合抗原受体T细胞治疗血液系统恶性肿瘤相关毒性机制研究进展[J].新乡医学院学报,2020,37(4):397-400.[doi:10.7683/xxyxyxb.2020.04.022]
点击复制

嵌合抗原受体T细胞治疗血液系统恶性肿瘤相关毒性机制研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年4
页码:
397-400
栏目:
综述
出版日期:
2020-04-05

文章信息/Info

作者:
卫延辉1; 郭学军2
（1.新乡医学院，河南　新乡　453003；2.濮阳市油田总医院血液科，河南　濮阳　457000)
关键词:
嵌合抗原受体T细胞;  恶性血液病;  免疫治疗;  不良反应
分类号:
R733
DOI:
10.7683/xxyxyxb.2020.04.022
文献标志码:
A
摘要:
目前，免疫治疗为恶性肿瘤的治疗提供了一种全新的方式，嵌合抗原受体T（CAR-T）细胞作为免疫治疗的一种方法，在治疗血液系统恶性肿瘤方面取得了巨大成功，尤其是在治疗B细胞相关性恶性血液病方面取得了显著疗效。CAR-T细胞在治疗B细胞相关性恶性血液病时，在发挥靶向性杀伤肿瘤细胞的同时也产生了一系列的毒性反应，严重者甚至导致患者死亡。掌握治疗过程中可能出现的并发症及应对措施，尽可能降低患者在治疗过程中的毒性反应及病死率，成为CAR-T细胞治疗成功的关键。本文将CAR-T细胞治疗B细胞相关性恶性血液病过程中出现的毒性反应机制做一综述。

参考文献/References:

［1］　TURTLE C J,HANAFI L A，BERGER C,et al.Immunotherapy of non-hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19- specific chimeric antigen receptor-modified T cells［J］.Sci Transl Med,2016,8(355):355ra116.
［2］　ZHANG X,LI J J,LU P H.Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia［J］.Chin Med J，2020,133: 474-482.
［3］　KOCHENDERFER J N,DUDLEY M E,KASSIM S H,et al.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor［J］.J Clin Oncol,2015,33(6):540-549.
［4］　NEELAPU S S,TUMMALA S,KEBRIAEI P,et al.Chimeric antigen receptor T-cell therapy-assessment and management of toxicities［J］.Nat Rev Clin Oncol，2018,15(1):47-62.
［5］　王雪莹,石琳,程志.嵌合抗原受体修饰T细胞治疗血液系统恶性肿瘤研究进展［J］.新乡医学院学报,2019,36(2):111-115.
［6］　ADKINS S.CAR T-cell therapy: adverse events and management［J］.J Adv Pract Oncol,2019,10(suppl 3):21-28.
［7］　LEE D W,GARDNER R,PORTER D L,et al.Current concepts in the diagnosis and management of cytokine release syndrome ［J］.Blood,2014,124(2): 188-195.
［8］　THAKAR M S,KEARL T J,MALAKANNAN S.Controlling cytokine release syndrome to harness the full potential of CAR-based cellular therapy［J］.Front Oncol,2019,9:1529.
［9］　TEACHEY D T,LACEY S F,SHAW P A,et al.Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia［J］.Cancer Discov,2016,6(6):664-679.
［10］　TITOV A,PETUKHOV A,STALIAROVA A,et al.The biological basis and clinical symptoms of CAR-T therapy-associated toxicites［J］.Cell Death Dis，2018，9(9):897.
［11］　GARCIA B JO,GODEL P,RUGER M A,et al.In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy［J］.Hemasphere,2019,3:e191.
［12］　MAUDE S L,FREY N,SHAW P A,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia ［J］.N Engl J Med,2014,371(16): 1507-1517.
［13］　LOCKE F L,NEELAPU S S,BARTLETT N L,et al.Phase 1 Results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma［J］.Mol Ther,2017,25(1):285-295.
［14］　CURRAN K J,MARGOSSIAN S P,KEMAN N A,et al.Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL［J］.Blood,2019,134:2361-2368.
［15］　MARGHERITA N,BARBARA C,GIULIA B,et al.Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells［J］.Nat Med,2018,24(6):739-748.
［16］　VALENTIJN K M,SADLER J E,VALENTIJN J A,et al.Functional architecture of Weibel-Palade bodies［J］.Blood,2011,117(19):5033-5043.
［17］　TANAKA T,NARAZAKI M,KISHIMOTO T.IL-6 in inflammation,immunity,and disease［J］.Csh Perspect Biol，2014,6(10):a016295.
［18］　MACKALL C L,MIKLOS D B.CNS endothelial cell activation emerges as adriver of CAR T cell-associated neurotoxicity［J］.Cancer Discov，2017,7(12):1371-1373.
［19］　SINGH N,HOFMANN T J,GERSHENSON Z,et al.Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function［J］.Cytotherapy,2017,19(7):867-880.
［20］　FRAIETTA J A,LACEY S F,ORLANDO E J,et al.Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia［J］.Nat Med,2018,24: 563-571.
［21］　DAVILA M L,RIVIERE I,WANG X,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia［J］.Sci Transl Med,2014,6(224): 224ra225.
［22］　FLIERL M A,RITTIRSCH D,NADEAU B A,et al.Upregulation of phagocyte-derived catecholaminesaugments the acute inflammatory response［J］.PLoS One,2009,4(2)：e4414.
［23］　FLIERL M A,RITTIRSCH D,HUBER-LANG M,et al.Catecholamines - Crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening Pandora′s box［J］.Mol Med,2008,14(3/4):195-204.
［24］　STAEDTKE V,BAI R Y,KIM K,et al.Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome ［J］.Nature，2018,564(7735):273-277.
［25］　LEE D W,KOCHENDERFER J N,STETLER-STEVENSON M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial［J］.Lancet,2015,385(9967):517.
［26］　BRENTJENS R J,DAVILA M L,RIVIERE I,et al.CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia［J］.Sci Transl Med,2013,5(177):177ra38.
［27］　MUELLER K T,MAUDE S L,PORTER D L,et al.Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia［J］.Blood,2017,130: 2317-2325.
［28］　TURTLE C J,HANAFI L A,BERGER C,et al.CD19 CAR-T cells of defined CD4+∶CD8+ composition in adult B cell ALL patients［J］.J Clin Invest，2016， 126(6):2123-2138.
［29］　GUST J,TARASEVICIUTE A,TURTLE C J.Neurotoxicity associated with CD19-targeted CAR-T cell therapies［J］.CNS Drugs,2018,32:1091-1101.
［30］　UCKUN F M,JASZCZ W,AMBRUS J L,et al.Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins［J］.Blood，1988，71:13-29.
［31］　MAUDE S L,BARRETT D,TEACHEY D T,et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies［J］.Cancer J,2014,20(2):119-122.
［32］　HU Y,SUN J,WU Z,et al.Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy［J］.J Hematol Oncol,2016,9(1):70.
［33］　GUST J,HAY K A,HANAFI L A,et al.Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells［J］.Cancer Discov，2017,7(12):1404-1419 .
［34］　HENTER J.HLH-2004 : diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis［J］.Pediatr Blood Cancer,2007,48(2):124-131.
［35］　RAMANAN A.Macrophage activation syndrome-what′s in a name［J］.J Rheumatol，2003,30(12):2513.
［36］　LAVIN Y,MORTHA A,RAHMAN A,et al.Regulation of macrophage development and function in peripheral tissues［J］.Nat Rev Immunol,2015,15(12):731-744.
［37］　侯丽娜,赵鲁杭.巨噬细胞表面的主要模式识别受体研究进展［J］.国际免疫学杂志,2005,28(4):249-252.
［38］　MOSSER D M,EDWARDS J P.Exploring the full spectrum of macrophage activation［J］.Nat Rev Immunol,2008,8:958-969.
［39］　MORGAN R A,YANG J C,KITANO M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2［J］.Mol Ther,2010,18(4):843-851．
［40］　KOCHENDERFER J N,DUDLEY M E,FELDMEN S A,et al.B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor- transduced T cells［J］.Blood,2012,119(12): 2709- 2720.
［41］　RUSSO V,BONDANZA A,CICERI F,et al.A dual role for genetically modified lymphocytes in cancer immunotherapy［J］.Trends Mol Med,2012,18(4):193-200.
［42］　STRAATHOF K C,PULE M A,YOTNDA P,et al.An inducible caspase 9 safety switch for T-cell therapy［J］.Blood,2005,105(11):4247-4254．
［43］　XIE Z H,CHAN E,YIN Y，et al.Inflammatory markers of the systemic capillary leak syndrome (clarkson disease)［J］.J Clin Cell Immunol,2014,5:1000213.
［44］　XIE Z,GHOSH C C,PARIKH S M,et al.Mechanistic classification of the systemic capillary leak syndrome: Clarkson disease.［J］.Am J Respir Crit Care Med,2014,189:1145-1147.
［45］　陈源美，张琪.毛细血管渗漏综合征发病机制的研究进展［J］.中国小儿急救医学,2019,26(6):461-465.
［46］　张永利,万献尧.毛细血管渗漏综合征［J］.中国医师进修杂志，2006，29(34):10-13.

相似文献/References:

[1]王雪莹,石　琳,程　志.嵌合抗原受体修饰T细胞治疗血液系统恶性肿瘤研究进展[J].新乡医学院学报,2019,36(2):111.[doi:10.7683/xxyxyxb.2019.02.003]
[2]董蕾,关晨阳,张莹,等.症状群信息化管理平台的建立及其在接受嵌合抗原受体T细胞免疫治疗淋巴瘤患者中的应用效果[J].新乡医学院学报,2023,40(2):169.[doi:10.7683/xxyxyxb.2023.02.014]
　DONG Lei,GUAN Chenyang,ZHANG Ying,et al.Establishment of symptom cluster information management platform and its application effect in lymphoma patients receiving chimeric antigen receptor T cell immunotherapy[J].Journal of Xinxiang Medical University,2023,40(4):169.[doi:10.7683/xxyxyxb.2023.02.014]

更新日期/Last Update: 2020-04-05